glp·helper
glphelper.com/zepbound/texas/the-woodlands
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in The Woodlands, TX

Verified Zepbound providers in The Woodlands, TX. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Zepbound weight loss →trial-anchored estimate
city providers
22
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Texas
23 of 23 shown

Find a Zepbound provider in Texas.

Every entry is checked against the NPI registry and the Texas medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Texas city · /zepbound/texas/{city}
§ 03Getting Zepbound in The Woodlands
23 providers · The Woodlands, TX

How to get Zepbound in The Woodlands.

23 GLP-1 prescribers and 7 local resource types are on record for The Woodlands, plus 3 nearby towns in the directory.

Prescribers in The Woodlands
23 prescribers
23 GLP-1 prescribers in The Woodlands, most listed as Family Medicine (13), Internal Medicine, Endocrinology, Diabetes & Metabolism (4) and Internal Medicine (4). Any Texas-licensed physician, nurse practitioner, or PA can prescribe Zepbound, over video or in person. The nearest towns on record are Conroe (24 providers), Spring (29 providers) and Houston (37 providers).
Around the prescription in The Woodlands
7 listed nearby
6 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near The Woodlands.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition)
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in The Woodlands

The Woodlands, Texas has a population of 114,436 people. The adult obesity rate in The Woodlands is an age-adjusted estimate of 27.7%, 7.9 percentage points below the Texas state rate of 35.6%. Diagnosed diabetes reaches 8.4% of adults in The Woodlands. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 17% of adults in The Woodlands.

of The Woodlands adults have obesity
27.7%
diagnosed diabetes
8.4%
no regular physical activity
17%

Age-adjusted estimates for The Woodlands, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s and hair loss
§ 05Support around Zepbound in The Woodlands
6 gyms

The prescription is one part. Here is the rest, in The Woodlands.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near The Woodlands, TX, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Fitness Connection
GYM
4.6 on Google · 2649 reviews
129 Sawdust Rd
Website
24 Hour Fitness
GYM
4.3 on Google · 1746 reviews
1800 Lake Woodlands Dr
Website
FITNESS PROJECT: Magnolia
GYM
4.1 on Google · 979 reviews
6511 FM 1488
Website
LA Fitness
GYM
3.7 on Google · 882 reviews
20127 I-45
Website
Villa Sport Athletic Club
GYM
4.0 on Google · 715 reviews
4141 Technology Forest Blvd
Website
LGND Barbell Co.
GYM
4.6 on Google · 681 reviews
26803 Hanna Rd Ste 808
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Tania Agrait, RD, LD, CBC
RD
Registered dietitian
18 Jaden Oaks Pl
Call 281-638-4895NPI 1154128130
Leilani Bayer, M.S., R.D.N., L.D
RD
Registered dietitian
395 Sawdust Rd Ste 2025
Call 844-532-7623NPI 1326430034
Camilla Blanton, RD, LD, CEDS
RD
Registered dietitian
8000 Research Forest Dr
Call 469-321-6064NPI 1134733470
Elissa Bradberry, RD, LD, CEDS
RD
Registered dietitian
17350 St Lukes Way Ste 220
Call 281-465-9229NPI 1417831512
Laura Brimer, MS, RD, LD
RD
Registered dietitian
2 Cattail Pl
Call 512-755-1568NPI 1215794946
Grace Carroll, MS, RD, LD
RD
Registered dietitian
15 Dakota Ridge Pl
Call 281-202-2298NPI 1154020519
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Zepbound cash price (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Commercial insurance (weight)
Often denied
On-label for obesity but frequently requires prior authorization
Medicare Part D
Not covered
Weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance with coverage only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Zepbound providers in Texas

NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Zepbound in other states

Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Zepbound in Texas

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]